Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines - PubMed (original) (raw)
L Schneider, R Doody, R Anand, H Feldman, H Haraguchi, R Kumar, U Lucca, C A Mangone, E Mohr, J C Morris, S Rogers, T Sawada
Affiliations
- PMID: 9305508
Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines
B Reisberg et al. Alzheimer Dis Assoc Disord. 1997.
Abstract
Following is the report of the committee working on clinical global measures for antidementia drug guidelines. The concepts involved in global scales, the distinctions between change and severity scales, advantages and disadvantages of structured interviews, and anchoring of change scores are discussed, and selected existing clinical global scales are described. In addition, the committee assessed the utility of global scales in clinical trials for antidementia drugs. There was a consensus among the members of the working group on the following: (1) Clinical global scales are interview based; in most cases, they include information obtained from caregivers as well as directly from patients, but they can rely on information from the subject only. (2) Clinicians' global ratings are intended to assess clinically meaningful change based on multidimensional clinical assessment and take into account the clinical heterogeneity of dementia by assessing at least cognition, behavior, and functioning. (3) There are two distinct types of clinical global measures: (a) clinicians' interview-based global severity scales, which generally incorporate classification by stage or severity of illness and (b) clinicians' interview-based global change scales, which incorporate global assessment ratings of clinical change. The committee could not reach a consensus on whether global scales should be required in phase II and phase III clinical trials, or whether other specific assessments such as well-designed activities of daily living, cognition, and behavior measures could, when used in appropriate combinations, replace the global as assessments of clinical meaningfulness.
Similar articles
- Activities of daily living as an outcome measure in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
Gauthier S, Bodick N, Erzigkeit E, Feldman H, Geldmacher DS, Huff J, Mohs R, Orgogozo JM, Rogers S. Gauthier S, et al. Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:6-7. Alzheimer Dis Assoc Disord. 1997. PMID: 9305507 No abstract available. - Translation issues in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
Feldman H, Anand R, Blesa R, Dubois B, Gray J, Homma A, Mohr E, Morris JC, Parys W, Raschig A, Robillard A. Feldman H, et al. Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:61-4. Alzheimer Dis Assoc Disord. 1997. PMID: 9305520 No abstract available. - Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines.
Ferris SH, Lucca U, Mohs R, Dubois B, Wesnes K, Erzigkeit H, Geldmacher D, Bodick N. Ferris SH, et al. Alzheimer Dis Assoc Disord. 1997;11 Suppl 3:34-8. Alzheimer Dis Assoc Disord. 1997. PMID: 9305514 No abstract available. - Outcome measures for probable vascular dementia and Alzheimer's disease with cerebrovascular disease.
Gauthier S, Ferris S. Gauthier S, et al. Int J Clin Pract Suppl. 2001 May;(120):29-39. Int J Clin Pract Suppl. 2001. PMID: 11406924 Review. - [Evaluation scales used in the demented patient].
Pepersack T. Pepersack T. Rev Med Brux. 2002 Jun;23(3):150-5. Rev Med Brux. 2002. PMID: 12143153 Review. French.
Cited by
- Dementia trials and dementia tribulations: methodological and analytical challenges in dementia research.
Ritchie CW, Terrera GM, Quinn TJ. Ritchie CW, et al. Alzheimers Res Ther. 2015 Mar 18;7(1):31. doi: 10.1186/s13195-015-0113-6. eCollection 2015. Alzheimers Res Ther. 2015. PMID: 25788988 Free PMC article. - Rivastigmine in Alzheimer's disease: Cognitive function and quality of life.
Annicchiarico R, Federici A, Pettenati C, Caltagirone C. Annicchiarico R, et al. Ther Clin Risk Manag. 2007 Dec;3(6):1113-23. Ther Clin Risk Manag. 2007. PMID: 18516265 Free PMC article. - Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.
Feldman HH, Lane R; Study 304 Group. Feldman HH, et al. J Neurol Neurosurg Psychiatry. 2007 Oct;78(10):1056-63. doi: 10.1136/jnnp.2006.099424. Epub 2007 Mar 12. J Neurol Neurosurg Psychiatry. 2007. PMID: 17353259 Free PMC article. Clinical Trial. - Memantine for dementia.
McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, Maayan N, Ware J, Debarros J. McShane R, et al. Cochrane Database Syst Rev. 2019 Mar 20;3(3):CD003154. doi: 10.1002/14651858.CD003154.pub6. Cochrane Database Syst Rev. 2019. PMID: 30891742 Free PMC article. - A systematic review of assessment and treatment of moderate to severe Alzheimer's disease.
Schmitt FA, Wichems CH. Schmitt FA, et al. Prim Care Companion J Clin Psychiatry. 2006;8(3):158-9. doi: 10.4088/pcc.v08n0306. Prim Care Companion J Clin Psychiatry. 2006. PMID: 16912819 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Medical